OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
November 11, 2021 16:05 ET
|
OpGen, Inc.
Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021, was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020Cash balance was further...
OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock
November 04, 2021 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Appoints Albert Weber as Chief Financial Officer
November 04, 2021 07:30 ET
|
OpGen, Inc.
Albert Weber to join OpGen as OpGen’s CFO effective January 1, 2022 from U.S.-German molecular diagnostics company EpigenomicsAnnounces inducement grant of 210,000 stock options under NASDAQ Listing...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time
October 28, 2021 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...
OpGen Subsidiary Ares Genetics Launches AREScloud
October 21, 2021 07:30 ET
|
OpGen, Inc.
AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolatesAREScloud offers an advanced solution for infection prevention and control ROCKVILLE,...
OpGen Announces Closing of $15 Million Registered Direct Offering
October 18, 2021 16:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces $15 Million Registered Direct Offering
October 14, 2021 08:00 ET
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021
October 04, 2021 07:30 ET
|
OpGen, Inc.
Preliminary Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021 was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020OpGen...
OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel
October 04, 2021 07:30 ET
|
OpGen, Inc.
OpGen’s Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogensAn aid to clinicians in the management of...
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
September 30, 2021 07:30 ET
|
OpGen, Inc.
OpGen’s Unyvero Urinary Tract Infection (UTI) Panel tests for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimensProspective multicenter trial...